Home › Research › How common it is
ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies
Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC.. Molecular neurodegeneration, 2022-11-08
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD) is the most common cause of dementia worldwide, and its prevalence is rapidly increasing due to extended lifespans. Among the increasing number of genetic risk factors identified, the apolipoprotein E (APOE) gene remains the strongest and most prevalent, impacting more than half of all AD cases. While the ε4 allele of the APOE gene significantly increases AD risk, the ε2 allele is protective relative to the common ε3 allele. These gene alleles encode three apoE protein isoforms that differ at two amino acid positions. The primary physiological function of apoE is to mediate lipid transport in the brain and periphery; however, additional functions of apoE in diverse biological functions have been recognized. Pathogenically, apoE seeds amyloid-β (Aβ) plaques in the brain with apoE4 driving earlier and more abundant amyloids. ApoE isoforms also have differential effects on multiple Aβ-related or Aβ-independent pathways. The complexity of apoE biology and pathobiology presents challenges to designing effective apoE-targeted therapeutic strategies. This review examines the key pathobiological pathways of apoE and related targeting strategies with a specific focus on the latest technological advances and tools.
What this study adds
Evidence grade: Low
This is a narrative review. This review describes how the APOE gene, especially the ε4 allele, increases Alzheimer's disease risk while the ε2 allele is protective, and how apoE relates to amyloid-beta. It discusses challenges in designing apoE-targeted therapeutic strategies but reports no proven treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Raulin, A. C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C. C. (2022). ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. Molecular neurodegeneration. https://doi.org/10.1186/s13024-022-00574-4
Vancouver
Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC. ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. Molecular neurodegeneration. 2022. doi:10.1186/s13024-022-00574-4. PMID: 36348357.
BibTeX
@article{raulin2022-36348357,
author = {Raulin, A. C. and Doss, S. V. and Trottier, Z. A. and Ikezu, T. C. and Bu, G. and Liu, C. C.},
title = {{ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies}},
journal = {Molecular neurodegeneration},
year = {2022},
doi = {10.1186/s13024-022-00574-4},
pmid = {36348357},
url = {https://doi.org/10.1186/s13024-022-00574-4}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- While the ε4 allele of the APOE gene significantly increases AD risk, the ε2 allele is protective relative to the common ε3 allele.
Why it matters
This review describes how the APOE gene, especially the ε4 allele, increases Alzheimer's disease risk while the ε2 allele is protective, and how apoE relates to amyloid-beta. It discusses challenges in designing apoE-targeted therapeutic strategies but reports no proven treatment or cure.
New to this subject? Start with our plain-English guide: Alzheimer's in numbers →
Study details
- Evidence strengthLow
How this study scored 54/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular neurodegeneration) |
| Journal's citation record | 2 / 4 | Molecular Neurodegeneration: journal h-index 164 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 751 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 125.2 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 6 / 6 | Cited 69.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 28 other studies in this library |
| Still being cited | 4 / 4 | Cited 669 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Chia‐Chen Liu: h-index 57 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Mayo Clinic in Florida: institution h-index 681 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36348357) |
| Free to read | 2 / 2 | Free to read |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13024-022-00574-4
- PubMed: 36348357
- Original source →
- Free full text: Molecular Neurodegeneration →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 70.
Later studies that cite this one
28 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in How common it is from nearby years
Also in How common it is
80 studies in the library are filed under How common it is with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The How common it is hub.